Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 168

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

20 years studying p53 functions in genetically engineered mice

Donehower, Lawrence A., Lozano, Guillermina·2009·Nature Reviews Cancer
DOI 10.1038/nrc2731
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc2731

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 98

  1. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997). · DOI · Paper page
  2. Palmiter, R. D. & Brinster, R. L. Germ-line transformation of mice. Annu. Rev. Genet. 20, 465–499 (1986). · DOI · Paper page
  3. Capecchi, M. R. Altering the genome by homologous recombination. Science 244, 1288–1292 (1989). · DOI · Paper page
  4. Bradley, A., Ramirez-Solis, R., Zheng, H., Hasty, P. & Davis, A. Genetic manipulation of the mouse via gene targeting in embryonic stem cells. Ciba Found. Symp. 165, 256–69 (1992).
  5. Lavigueur, A. et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9, 3982–3991 (1989). · DOI · Paper page
  6. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990). · DOI · Paper page
  7. Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W. & Chang, E. H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome. Nature 348, 747–749 (1990). · DOI · Paper page
  8. Varley, J. M. Germline TP53 mutations and Li–Fraumeni syndrome. Hum. Mutat. 21, 313–320 (2003). · DOI · Paper page
  9. Bachinski, L. L. et al. Genetic mapping of a third Li–Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res. 65, 427–431 (2005). · DOI
  10. Tsukada, T. et al. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8, 3313–3322 (1993).
  11. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1–7 (1994). · DOI · Paper page
  12. Purdie, C. A. et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9, 603–609 (1994).
  13. Lee, E. Y. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288–294 (1992). · DOI · Paper page
  14. Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295–300 (1992). · DOI · Paper page
  15. Matzuk, M. M., Finegold, M. J., Su, J. G., Hsueh, A. J. & Bradley, A. α-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360, 313–319 (1992). · DOI · Paper page
  16. Armstrong, J. F., Kaufman, M. H., Harrison, D. J. & Clarke, A. R. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5, 931–936 (1995). · DOI · Paper page
  17. Sah, V. P. et al. A subset of p53-deficient embryos exhibit exencephaly. Nature Genet. 10, 175–180 (1995). · DOI · Paper page
  18. Marine, J. C. & Lozano, G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 5 Jun 2009 (doi: 10.1038/cdd.2009.68). · DOI · Paper page
  19. de Rozieres, S., Maya, R., Oren, M. & Lozano, G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19, 1691–1697 (2000). · DOI
  20. Donehower, L. A. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol. 7, 269–278 (1996). · DOI · Paper page
  21. Venkatachalam, S. et al. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/− mouse model in carcinogenicity testing. Toxicol. Pathol. 29, 147–154 (2001). · DOI
  22. Knudson, A. G. Jr, Hethcote, H. W. & Brown, B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. Natl Acad. Sci. USA 72, 5116–5120 (1975). · DOI · Paper page
  23. Knudson, A. G. Jr. Genetics of human cancer. Annu. Rev. Genet. 20, 231–251 (1986). · DOI · Paper page
  24. Venkatachalam, S. et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17, 4657–4667 (1998). · DOI · Paper page
  25. Blackburn, A. C. et al. Loss of heterozygosity occurs via mitotic recombination in Trp53+/− mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res. 64, 5140–5147 (2004). · DOI
  26. Attardi, L. D. & Donehower, L. A. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat. Res. 576, 4–21 (2005). · DOI
  27. Lozano, G. The oncogenic roles of p53 mutants in mouse models. Curr. Opin. Genet. Dev. 17, 66–70 (2007). · DOI
  28. Johnson, T. M. & Attardi, L. D. Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice. Cell Death Differ. 13, 902–908 (2006). · DOI
  29. Clarke, A. R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849–852 (1993). · DOI · Paper page
  30. Sigal, A. & Rotter, V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788–6793 (2000).
  31. Dittmer, D. et al. Gain of function mutations in p53. Nature Genet. 4, 42–46 (1993). · DOI · Paper page
  32. Liu, G. et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl Acad. Sci. USA 97, 4174–4179 (2000). · DOI · Paper page
  33. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119, 861–872 (2004). · DOI · Paper page
  34. Terzian, T. et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 1337–1344 (2008). · DOI · Paper page
  35. Ljungman, M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2, 208–225 (2000). · DOI
  36. Eischen, C. M. & Lozano, G. p53 and MDM2: antagonists or partners in crime? Cancer Cell 15, 161–162 (2009). · DOI
  37. McDonnell, T. J. et al. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J. Pathol. 188, 322–328 (1999). · DOI · Paper page
  38. Flores, E. R. et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363–373 (2005). · DOI · Paper page
  39. el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993). · DOI · Paper page
  40. Barboza, J. A., Liu, G., Ju, Z., El-Naggar, A. K. & Lozano, G. p21 delays tumor onset by preservation of chromosomal stability. Proc. Natl Acad. Sci. USA 103, 19842–19847 (2006). · DOI
  41. Iwakuma, T. & Lozano, G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 26, 2177–2184 (2007). · DOI
  42. Armata, H. L., Garlick, D. S. & Sluss, H. K. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res. 67, 11696–11703 (2007). · DOI
  43. Chao, C., Herr, D., Chun, J. & Xu, Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J. 25, 2615–2622 (2006).
  44. Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. & Berns, A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994–1004 (2000). · DOI · Paper page
  45. Berman, S. D. et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc. Natl Acad. Sci. USA 105, 11851–11856 (2008). · DOI · Paper page
  46. Lengner, C. J. et al. Osteoblast differentiation and skeletal development are regulated by Mdm2–p53 signaling. J. Cell. Biol. 172, 909–921 (2006). · DOI · Paper page
  47. Lin, S. C. et al. Somatic mutation of p53 leads to estrogen receptor α-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 64, 3525–3532 (2004). · DOI
  48. Walkley, C. R. et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 22, 1662–1676 (2008). · DOI · Paper page
  49. Hinkal, G. W., Parikh, N. & Donehower, L. A. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS ONE 4, e6654 (2009). · DOI
  50. Seibler, J. et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res. 31, e12 (2003). · DOI · Paper page
  51. Wijnhoven, S. W. et al. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res. 65, 8166–8173 (2005). · DOI
  52. Christophorou, M. A. et al. Temporal dissection of p53 function in vitro and in vivo. Nature Genet. 37, 718–726 (2005). · DOI · Paper page
  53. Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B. & Evan, G. I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501–514 (2006). · DOI · Paper page
  54. Nicol, C. J., Harrison, M. L., Laposa, R. R., Gimelshtein, I. L. & Wells, P. G. A teratologic suppressor role for p53 in benzo(a)pyrene-treated transgenic p53-deficient mice. Nature Genet. 10, 181–187 (1995). · DOI · Paper page
  55. Norimura, T., Nomoto, S., Katsuki, M., Gondo, Y. & Kondo, S. p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nature Med. 2, 577–580 (1996). · DOI
  56. Wang, B. Involvement of p53-dependent apoptosis in radiation teratogenesis and in the radioadaptive response in the late organogenesis of mice. J. Radiat. Res. 42, 1–10 (2001). · DOI
  57. Finch, R. A. et al. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 62, 3221–3225 (2002).
  58. Hu, W., Feng, Z., Teresky, A. K. & Levine, A. J. p53 regulates maternal reproduction through LIF. Nature 450, 721–724 (2007). · DOI · Paper page
  59. Kay, C., Jeyendran, R. S. & Coulam, C. B. p53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. Reprod. Biomed. Online 13, 492–496 (2006). · DOI
  60. Hu, W., Feng, Z., Atwal, G. S. & Levine, A. J. p53: a new player in reproduction. Cell Cycle 7, 848–852 (2008). · DOI
  61. de Vries, A. et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl Acad. Sci. USA 99, 2948–2953 (2002). · DOI · Paper page
  62. Maier, B. et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306–319 (2004). · DOI · Paper page
  63. Garcia-Cao, I. et al. “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21, 6225–6235 (2002).
  64. Ferbeyre, G. & Lowe, S. W. The price of tumour suppression? Nature 415, 26–27 (2002). · DOI
  65. Dumble, M. et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 109, 1736–1742 (2007). · DOI · Paper page
  66. Akala, O. O. et al. Long-term haematopoietic reconstitution by Trp53−/−p16 Ink4A−/−p19 Arf−/− multipotent progenitors. Nature 453, 228–232 (2008). · DOI · Paper page
  67. Gatza, C., Moore, L., Dumble, M. & Donehower, L. A. Tumor suppressor dosage regulates stem cell dynamics during aging. Cell Cycle 6, 52–55 (2007). · DOI
  68. Bourdon, J. C. p53 Family isoforms. Curr. Pharm. Biotechnol. 8, 332–336 (2007). · DOI
  69. Mills, A. A. p63: oncogene or tumor suppressor? Curr. Opin. Genet. Dev. 16, 38–44 (2006). · DOI
  70. Rosenbluth, J. M. & Pietenpol, J. A. The jury is in: p73 is a tumor suppressor after all. Genes Dev. 22, 2591–2595 (2008). · DOI
  71. Mills, A. A. et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708–713 (1999). · DOI · Paper page
  72. Yang, A. et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714–718 (1999). · DOI · Paper page
  73. Keyes, W. M. et al. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 19, 1986–1999 (2005). · DOI · Paper page
  74. Keyes, W. M. et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc. Natl Acad. Sci. USA 103, 8435–8440 (2006). · DOI
  75. Yang, A. et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99–103 (2000). · DOI · Paper page
  76. Tomasini, R. et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22, 2677–2691 (2008). · DOI · Paper page
  77. Tomasini, R., Mak, T. W. & Melino, G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 18, 244–252 (2008). · DOI
  78. Kuperwasser, C. et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li—Fraumeni syndrome. Am. J. Pathol. 157, 2151–2159 (2000). · DOI · Paper page
  79. Harvey, M., McArthur, M. J., Montgomery, C. A. Jr, Bradley, A. & Donehower, L. A. Genetic background alters the spectrum of tumors that develop in p53- deficient mice. FASEB J. 7, 938–943 (1993). · DOI · Paper page
  80. Johnson, T. M., Hammond, E. M., Giaccia, A. & Attardi, L. D. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nature Genet. 37, 145–152 (2005). · DOI
  81. Nister, M. et al. p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene 24, 3563–3573 (2005). · DOI
  82. Chao, C. et al. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26, 6859–6869 (2006). · DOI
  83. Krummel, K. A., Lee, C. J., Toledo, F. & Wahl, G. M. The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl Acad. Sci. USA 102, 10188–10193 (2005). · DOI · Paper page
  84. Luo, J. L. et al. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20, 320–328 (2001). · DOI
  85. Song, H., Hollstein, M. & Xu, Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nature Cell Biol. 9, 573–580 (2007). · DOI · Paper page
  86. Johnson, T. M., Meade, K., Pathak, N., Marques, M. R. & Attardi, L. D. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc. Natl Acad. Sci. USA 105, 1215–1220 (2008). · DOI
  87. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet. 29, 418–425 (2001). · DOI · Paper page
  88. Ghebranious, N. & Sell, S. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology 27, 967–973 (1998). · DOI
  89. Li, B., Rosen, J. M., McMenamin-Balano, J., Muller, W. J. & Perkins, A. S. neu/ERBB2 cooperates with p53–172H during mammary tumorigenesis in transgenic mice. Mol. Cell. Biol. 17, 3155–3163 (1997). · DOI
  90. Li, B. et al. Preferential overexpression of a 172Arg-->Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development. Cell Growth Differ. 5, 711–721 (1994).
  91. Hernandez, I. et al. Prostate-specific expression of p53R172L differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol. Cancer Res. 1, 1036–1047 (2003).
  92. Duan, W. et al. Lung-specific expression of human mutant p53–273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene 21, 7831–7838 (2002). · DOI
  93. Klein, M. A. et al. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. Oncogene 19, 5329–5337 (2000). · DOI
  94. Godley, L. A. et al. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev. 10, 836–850 (1996). · DOI
  95. Gillet, R. et al. The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents. Oncogene 19, 3498–3507 (2000). · DOI
  96. Kemp, C. J., Donehower, L. A., Bradley, A. & Balmain, A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813–822 (1993). · DOI · Paper page
  97. Howes, K. A. et al. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev. 8, 1300–1310 (1994). · DOI · Paper page
  98. Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335–346 (2002). · DOI · Paper page

Cited by

See all 168

Metadata

Authors
Donehower, L. A., & Lozano, G.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2009-09-24
Volume
9
Issue
11
Pages
831-841
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/nrc2731
Cited by
168
References
37
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 20 years studying p53 functions in genetically engineered mice. https://app.cochat.ai/papers/10.1038/nrc2731
The paper
Donehower, L. A., & Lozano, G. (2009). 20 years studying p53 functions in genetically engineered mice. Nature Reviews Cancer. https://doi.org/10.1038/nrc2731

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.